JON HAUTZENROEDER: Open Payments
NPI 1205300886 · AURORA, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$418 in 24 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $33 · 2025 $418
Food & beverage: $418
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $155 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| PFIZER INC. | 3 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| Amgen Inc. | 2 | $30 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Novo Nordisk Inc | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, NURTEC ODT, XIFAXAN, QULIPTA, INGREZZA, Ozempic, Kerendia.
Industry payments across IN — which companies pay providers there.
